Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.41
- Piotroski Score 6.00
- Grade Buy
- Symbol (ZYXI)
- Company Zynex, Inc.
- Price $8.27
- Changes Percentage (1.97%)
- Change $0.16
- Day Low $8.13
- Day High $8.30
- Year High $13.77
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
- Last Earnings 11/10/2021
- Ex-Dividend for 5/16 Dividend 01/05/2022
- Dividend Payable 01/21/2022
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $14.25
- High Stock Price Target $18.00
- Low Stock Price Target $11.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.23
- Trailing P/E Ratio 41.7
- Forward P/E Ratio 41.7
- P/E Growth 41.7
- Net Income $9.73 M
Income Statement
Quarterly
Annual
Latest News of ZYXI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
A Note On Zynex, Inc.'s (NASDAQ:ZYXI) ROE and Debt To Equity
ROE is a key metric to assess a company's ability to generate returns on shareholder investments. Zynex Inc. has an ROE of 13%, indicating its success in turning equity into profits. However, its high...
By Yahoo! Finance | 6 days ago -
Zynex Inc (ZYXI) Q3 2024 Earnings Call Highlights: Navigating Growth and Challenges
In the third quarter, orders growth decelerated but is expected to maintain double-digit growth in the fourth quarter and into next year. The strategic review process is ongoing, and no share repurcha...
By Yahoo! Finance | 4 weeks ago -
Zynex's (NASDAQ:ZYXI) Returns On Capital Not Reflecting Well On The Business
To identify a stock with potential for long-term value growth, look for increasing Return on Capital Employed (ROCE) and rising capital employed....
By Yahoo! Finance | 3 months ago
